Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The study will use previously established doses of panitumumab or cetuximab in the metastatic
setting for the treatment of unresectable colorectal cancer (CRC). It is designed to
investigate an alternative treatment strategy to maximize the benefit to inhibition of
epidermal growth factor receptor (EGFR) for a highly selected patient population. It will
enroll 110 participants with left-sided, unresectable metastatic CRC. Participants will be on
study up to 5 years.